ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 375

Cell Phone Based Automated Monitoring of Patients with Early Rheumatoid Arthritis

Kari Puolakka1, Tuulikki Sokka2 and Hannu Kautiainen3, 1Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 2Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 3Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Cell phone based automated monitoring of patients with early rheumatoid arthritis

 

Background/Purpose: Frequent monitoring improves patient compliance and outcomes of RA. Limited resources may hinder adherence to recommendations to frequent assessment. A remote assessment could be a solution with patient’s global assessment (PtGA) as a measure.

Methods: A novel, cell-phone based monitoring system has been invented (SandRA).

Each incident patient with early RA is being registered in SandRA monitoring – with his or her informed consent. Baseline PtGA is recorded. Every 2 weeks during the following 6 months, SandRA sends automatically an SMS to the patient’s cell phone, and patient answers by one push on keyboard. The first 2 SMSs concern medications (“Have you used the prescribed drug treatments?” Y/N) and adverse events (“Have you experienced any problems with the drug?” Y/N). From 6 weeks onwards, PtGAs is inquired: (“What is the severity of RA on scale 0 to 10, when 0 corresponds absence of RA symptoms and 10 as severe RA symptoms as you can imagine?”). Based on data from our previous early RA cohorts, a treatment target was set at 5-3/10 (figure 1).

The patients’ answers are recorded in SandRA database and automatically analyzed. If an answer does not indicate problems, patient receives an automatic SMS response of the answer being recorded. If an answer indicates problems, i.e., patient has not used the treatment, has experienced adverse events, or RA has not improved at the pace defined, the patient receives an SMS: “Your nurse will call you within 2 working days”. At the same time, the nurse receives an e-mail about the patient’s problem. If the problem cannot be solved on the phone, the patient is called for a visit for treatment adjustment.

Results: We analyzed 137 consecutive patients registered in SandRA. The patients’ regular doctor appointments were scheduled at 3 and 6 months. Most patients achieved the treatment target, i.e., their PtGAs were under the alarm line (panel A). SandRA picked out 34%, 31%, 29%, and 31% of the patients at 6, 10, 18, and 22 weeks for assessment before regular appointments (panel B).

Conclusion: A novel automated cell phone based monitoring system may provide a feasible method to achieve treatment target in patients with early RA.

 


Disclosure:

K. Puolakka,
None;

T. Sokka,
None;

H. Kautiainen,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cell-phone-based-automated-monitoring-of-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology